

12 Jun 2019 | News

## QUOTED. 12 June 2019. Tim Goodnow.

by

Senseonics will soon begin marketing its Eversense continuous glucose monitoring (CGM) system in the US as an alternative to fingerstick testing to help patients make diabetes treatment decisions throughout the day. See what CEO Tim Goodnow said about Eversense here.

“We expect [that Eversense] will allow our users to more conveniently and confidently live their lives with fewer interruptions.” – Tim Goodnow, CEO, Senseonics

- Find out more: [Continuous Glucose Monitor From Senseonics Earns FDA Approval For ‘Non-Adjunctive’ Claim](#)

[Click here](#) for a free trial of *Medtech Insight*